1
|
Bajaj P, Chowdhury SK, Yucha R, Kelly EJ, Xiao G. Emerging Kidney Models to Investigate Metabolism, Transport, and Toxicity of Drugs and Xenobiotics. Drug Metab Dispos 2018; 46:1692-1702. [PMID: 30076203 DOI: 10.1124/dmd.118.082958] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 08/01/2018] [Indexed: 01/11/2023] Open
Abstract
The kidney is a major clearance organ of the body and is responsible for the elimination of many xenobiotics and prescription drugs. With its multitude of uptake and efflux transporters and metabolizing enzymes, the proximal tubule cell (PTC) in the nephron plays a key role in the disposition of xenobiotics and is also a primary site for toxicity. In this minireview, we first provide an overview of the major transporters and metabolizing enzymes in the PTCs responsible for biotransformation and disposition of drugs. Next, we discuss different cell sources that have been used to model PTCs in vitro, their pros and cons, and their characterization. As current technology is inadequate to evaluate reliably drug disposition and toxicity in the kidney, we then discuss recent advancements in kidney microphysiological systems (MPS) and the need to develop robust in vitro platforms that could be routinely used by pharmaceutical companies to screen compounds. Finally, we discuss the new and exciting field of stem cell-derived kidney models as potential cell sources for future kidney MPS. Given the push from both regulatory agencies and pharmaceutical companies to use more predictive "human-like" in vitro systems in the early stages of drug development to reduce attrition, these emerging models have the potential to be a game changer and may revolutionize how renal disposition and kidney toxicity in drug discovery are evaluated in the future.
Collapse
Affiliation(s)
- Piyush Bajaj
- Drug Safety Research and Evaluation (P.B.) and Drug Metabolism and Pharmacokinetics Department (S.K.C., R.Y., G.X.), Takeda Pharmaceutical International Co., Cambridge, Massachusetts; and Department of Pharmaceutics, University of Washington, Seattle, Washington (E.J.K.)
| | - Swapan K Chowdhury
- Drug Safety Research and Evaluation (P.B.) and Drug Metabolism and Pharmacokinetics Department (S.K.C., R.Y., G.X.), Takeda Pharmaceutical International Co., Cambridge, Massachusetts; and Department of Pharmaceutics, University of Washington, Seattle, Washington (E.J.K.)
| | - Robert Yucha
- Drug Safety Research and Evaluation (P.B.) and Drug Metabolism and Pharmacokinetics Department (S.K.C., R.Y., G.X.), Takeda Pharmaceutical International Co., Cambridge, Massachusetts; and Department of Pharmaceutics, University of Washington, Seattle, Washington (E.J.K.)
| | - Edward J Kelly
- Drug Safety Research and Evaluation (P.B.) and Drug Metabolism and Pharmacokinetics Department (S.K.C., R.Y., G.X.), Takeda Pharmaceutical International Co., Cambridge, Massachusetts; and Department of Pharmaceutics, University of Washington, Seattle, Washington (E.J.K.)
| | - Guangqing Xiao
- Drug Safety Research and Evaluation (P.B.) and Drug Metabolism and Pharmacokinetics Department (S.K.C., R.Y., G.X.), Takeda Pharmaceutical International Co., Cambridge, Massachusetts; and Department of Pharmaceutics, University of Washington, Seattle, Washington (E.J.K.)
| |
Collapse
|
2
|
Blockade of the N-Methyl-D-Aspartate Glutamate Receptor Ameliorates Lipopolysaccharide-Induced Renal Insufficiency. PLoS One 2015; 10:e0132204. [PMID: 26133372 PMCID: PMC4489897 DOI: 10.1371/journal.pone.0132204] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 06/12/2015] [Indexed: 11/28/2022] Open
Abstract
N-methyl-D-aspartate (NMDA) receptor activation in rat kidney reduces renal perfusion and ultrafiltration. Hypoperfusion-induced ischemia is the most frequent cause of functional insufficiency in the endotoxemic kidney. Here, we used non-hypotensive rat model of lipopolysaccharide-induced endotoxemia to examine whether NMDA receptor hyperfunction contributes to acute kidney injury. Lipopolysaccharide-induced renal damage via increased enzymuria and hemodynamic impairments were ameliorated by co-treatment with the NMDA receptor blocker, MK-801. The NMDA receptor NR1 subunit in the rat kidney mainly co-localized with serine racemase, an enzyme responsible for synthesizing the NMDA receptor co-agonist, D-serine. The NMDA receptor hyperfunction in lipopolysaccharide-treated kidneys was demonstrated by NR1 and serine racemase upregulation, particularly in renal tubules, and by increased D-serine levels. Lipopolysaccharide also induced cell damage in cultured tubular cell lines and primary rat proximal tubular cells. This damage was mitigated by MK-801 and by small interfering RNA targeting NR1. Lipopolysaccharide increased cytokine release in tubular cell lines via toll-like receptor 4. The release of interleukin-1β from these cells are the most abundant. An interleukin-1 receptor antagonist not only attenuated cell death but also abolished lipopolysaccharide-induced NR1 and serine racemase upregulation and increases in D-serine secretion, suggesting that interleukin-1β-mediated NMDA receptor hyperfunction participates in lipopolysaccharide-induced tubular damage. The results of this study indicate NMDA receptor hyperfunction via cytokine effect participates in lipopolysaccharide-induced renal insufficiency. Blockade of NMDA receptors may represent a promising therapeutic strategy for the treatment of sepsis-associated renal failure.
Collapse
|
3
|
Silva AH, Filippin-Monteiro FB, Mattei B, Zanetti-Ramos BG, Creczynski-Pasa TB. In vitro biocompatibility of solid lipid nanoparticles. THE SCIENCE OF THE TOTAL ENVIRONMENT 2012; 432:382-388. [PMID: 22750185 DOI: 10.1016/j.scitotenv.2012.06.018] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 06/01/2012] [Accepted: 06/06/2012] [Indexed: 06/01/2023]
Abstract
This study was undertaken to address the current deficient knowledge of cellular response to solid lipid nanoparticles (SLNs) exposure. We investigated the cytotoxicity of several SLNs formulations in two fibroblast cell lineages, Vero and MDCK. Several methods were used to explore the mechanisms involved in this cytotoxic process, including cell viability assays, flow cytometry and ROS generation assessment. Among nanoparticles tested, two of them (F4 and F5) demonstrated more cytotoxic effects in both cell lineages. The cell viability assays suggested that F4 and F5 interfere in cell mitochondrial metabolism and in lysosomal activity. In addition, F5 decreased the percentage of MDCK cells in G0/G1 and G2/M phases, with a marked increase in the Sub/G1 population, suggesting DNA fragmentation. Regarding F4, although IC(50) was higher (~700 μg/mL), this formulation affected mitochondrial membrane potential for Vero cells. However, the IC(50) of F5 was around 250 μg/mL, suggesting the effect of SDS (sodium dodecyl sulfate) present in the formulation. In summary, the nanoparticles tested here appears to be biocompatible, with the exception of F5. Further studies are required to elucidate the in vivo effects of these nanoscale structures, in order to evaluate or predict the connotation of their increased and widespread use.
Collapse
Affiliation(s)
- Adny Henrique Silva
- Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina P.O. Box 476, Florianópolis, SC, 88040-900, Brazil
| | | | | | | | | |
Collapse
|
4
|
Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005; 27:116-22. [PMID: 15795639 DOI: 10.1097/01.ftd.0000148448.51225.2c] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A population pharmacokinetic analysis of cyclosporine (CsA) was performed, and the influence of covariates on CsA oral clearance and relative bioavailability was investigated. Data from 48 recipients of heart-lung (n = 21) or single (n = 18) or double (n = 9) lung transplant were included in the study. Patients received oral CsA as either a conventional formulation (Sandimmune) or a microemulsion (Neoral). Steady-state CsA concentrations were measured before and at approximately 2 and 6 hours after the morning dose of CsA at the end of weeks 1, 2, 3, 4, 13, 26, 39, and 52 posttransplantation. A total of 1004 CsA concentration observations were analyzed using mixed effects-modeling (NONMEM). A 1-compartment pharmacokinetic model and first-order oral absorption were used to fit the data. The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations. Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h). Itraconazole (ITRA), cystic fibrosis (CF), and weight (WT) were identified as significant covariates for CL/F according to the final model: CL/F = 22.1 - 11.3 x ITRA + 23.5 x CF + 0.129 x (WT - 58.7) L/h; where ITRA = 1 if the patient was taking concomitant itraconazole, otherwise 0; CF = 1 if the patient had cystic fibrosis, otherwise CF = 0; and WT is patient weight in kilograms. The relative oral bioavailability of Sandimmune to Neoral was 0.82. The bioavailability of both preparations increased during the first month posttransplantation. Age, gender, and type of transplant (single, double, or heart-lung) were not identified as significant covariates for CsA clearance. The population pharmacokinetic model developed identified some sources of variability in CsA pharmacokinetics; however, an appreciable degree of variability is still present in this patient population.
Collapse
Affiliation(s)
- Sara E Rosenbaum
- Department of Applied Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
| | | | | | | |
Collapse
|